drugset / Trial / NCT00163657
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
Phase 4
Completed
312 enrolled
Baylor Research Institute
Baylor Health Care System · collabEmory University · collabLahey Clinic · collabMayo Clinic - Rochester, Minnesota · collabMayo Clinic - Scottsdale/Phoenix, Arizona · collabMedical University of South Carolina · collabNew York Presbyterian Hospital · collabNew York University · collabNorthwestern Memorial Hospital · collabOregon Health and Science University · collabThe University of Texas Health Science Center at San Antonio · collabUniversity of Alabama at Birmingham · collabUniversity of California, San Francisco · collabUniversity of Chicago · collabUniversity of Cincinnati · collabUniversity of Medicine and Dentistry of New Jersey · collabUniversity of Southern California · collabUniversity of Virginia · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
Timeline
- Start
- 2002-07
- Primary completion
- 2006-04
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Comparator | Daclizumab | Monoclonal antibody | — | — |
| Comparator | MMF | Unknown | — | — |
| Comparator | Tacrolimus | Small molecule | — | — |